Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database

Gaetana Sterrantino, Mauro Zaccarelli, Antonio Di Biagio, Maria Luisa Biondi, Andrea Antinori, Giovanni Penco

Research output: Contribution to journalArticle

Abstract

Background: We assessed the virological response of dual therapy with DRV/r, plus raltegravir, maraviroc or etravirine, in virological failure patients and in virologically suppressed patients collected in the Italian Antiretroviral Resistance Database (ARCA). Material and methods: The primary endpoint was the percentage of patients remaining free of virological failure (confirmed >50 copies/mL or any change in the regimen). Subjects had a resistance test and at least one follow-up visit. Observation was censored at last visit under dual therapy and survival analysis and proportional hazard models were used. Results: Sixty-seven percent of the 221 patients started DRV/r with RAL, 20.4 % with ETV, and 12.2 % with MAR; 31.2 % virological failures were observed. At survival analysis, the overall proportion of failure was 29.2 % at 1 year and 33.8 % at 2 years. The proportion of failure was lower in patients starting with undetectable vs. detectable viral load (13.3 and 25.2 % vs. 37.4 and 38.8 % at 1 and 2 years, respectively, p = 0.001 for both analyses) and in patients treated with DRV 600 BID vs. 800 QD (HR: 0.56, 95 % CI: 0.31–0.99, p 

Original languageEnglish
Pages (from-to)339-343
Number of pages5
JournalInfection
Volume43
Issue number3
DOIs
Publication statusPublished - Mar 28 2015

Keywords

  • Darunavir/r dual therapy
  • Etravirine
  • Maraviroc
  • Raltegravir
  • Switching strategies

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Darunavir-based dual therapy of treatment-experienced HIV-infected patients: analysis from a national multicenter database'. Together they form a unique fingerprint.

  • Cite this